Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

The Omicron variant has three subvariants: BA. 1 (B. 1.1. 529.1), BA. 2 (B. 1.1. 529.2), and
BA. 3 (B. 1.1. 529.3). BA. 2 is found to be able to alarmingly reinfect patients originally …

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …

The devastating economic and public health consequences caused by the COVID-19
pandemic have prompted outstanding efforts from the scientific community and …

Extensive research in countries with high sociodemographic indices (SDIs) to date has
shown that coronavirus disease 2019 (COVID-19) may be directly associated with more …

Neutralizing antibodies (nAbs) are important assets to fight COVID-19, but most existing
nAbs lose the activities against Omicron subvariants. Here, we report a human monoclonal …

SARS-CoV-2 variants with adaptive mutations have continued to emerge, causing fresh
waves of infection even amongst vaccinated population. The development of broad …

Due to the continuous evolution of SARS-CoV-2, the Omicron variant has emerged and
exhibits severe immune evasion. The high number of mutations at key antigenic sites on the …

The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover
novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb …